{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003693","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.885532+00:00","generated_at":"2026-06-06T06:51:34.703260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda reports FY2023 revenue $192.6M (-24% YoY); Q4 net loss $2.4M; PDUFA dates in 2024","bullets":["Full year 2023 net product sales $192.6M, down 24% from $254.4M; Q4 net loss $2.4M vs income $6.9M in Q4 2022.","HETLIOZ sales fell 47% YoY in Q4 due to generic at-risk launches; Fanapt down 7%; PONVORY added $1.6M post-acquisition Dec 7.","Ended 2023 with $388.3M cash, down $78.6M; $100M spent on PONVORY acquisition.","Three PDUFA target action dates in 2024: HETLIOZ insomnia March 4 (FDA cited deficiencies, Vanda sued), Fanapt bipolar April 2, tradipitant gastroparesis Sept 18.","Vanda unable to provide 2024 financial guidance due to HETLIOZ patent litigation and generic competition."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003693","json":"https://secwatch.observer/filing/0001628280-24-003693.json","markdown":"https://secwatch.observer/filing/0001628280-24-003693.md","text":"https://secwatch.observer/filing/0001628280-24-003693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/0001628280-24-003693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/vnda-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:51:34.703260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eebb4303c81289b834e62ce64b9e58354d3f5064","claim":"Vanda Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 7, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/0001628280-24-003693-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}